Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real World Study of Anlotinib in Advanced Medullary Thyroid Carcinoma
NCT05830500Phase 4Recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jun 2023
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of anlotinib in medullary thyroid carcinoma (MTC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Jun 2023; status: recruiting.
02
Drugs
anlotinib
03
Conditions
medullary thyroid carcinoma (MTC)
Beyond the preview
Go deeper on NCT05830500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05830500.